Clinical Trials
11 trialsNCT07615751 2026-05-29
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
Fudan University
Phase 3 Recruiting
NCT06144944 2026-01-30
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Active not recruiting
NCT05910398 2025-11-18
CORINNE-PI
RenJi Hospital
Phase 3 Recruiting
NCT04254263 2025-09-11
ATP
RenJi Hospital
Phase 3 Recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05841381 2023-05-03
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University
Phase 3 Not yet recruiting
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT05346861 2022-04-26
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
Phase 3 Unknown
NCT04973319 2021-07-22
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Shengjing Hospital
Phase 3 Not yet recruiting
NCT04736589 2021-02-03
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College
Phase 3 Not yet recruiting
NCT04646759 2020-11-30
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting